Correlation of SLC22A1 (OCT1) Genetic Variants with Metformin Pharmacokinetic Response in the Management of Diabetes

Fareeda Islam; Muhammad Nauman Ahsun; Aeliya Batool

doi:10.70749/ijbr.v2i02.2618

Authors

Fareeda Islam Department of Pharmacology, Karachi Medical and Dental College, Karachi Metropolitan University, Karachi, Pakistan
Muhammad Nauman Ahsun Liaquat College of Medicine and Dentistry, Karachi, Pakistan
Aeliya Batool Department of Pharmacology, Karachi Medical and Dental College, Karachi Metropolitan University, Karachi, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v2i02.2618

Keywords:

GRK5, rs10886471, Repaglinide, Type 2 Diabetes Mellitus, Pharmacogenetics

Abstract

Type 2 Diabetes Mellitus (T2DM) presents a growing public health challenge globally, with marked inter-individual variability in response to oral hypoglycemic agents. Pharmacogenetics offers a promising approach to personalize therapy by linking genetic variations to drug efficacy. This study investigates the association between the GRK5 rs10886471 variant and therapeutic response to repaglinide in a cohort of Pakistani T2DM patients. A quasi-experimental design was employed, enrolling 63 patients who received repaglinide therapy, with responders and non-responders categorized based on HbA1c reduction. Socio-demographic and clinical data, including BMI, family history, and treatment history, were recorded. Genomic DNA was extracted from peripheral blood, and genotyping for GRK5 rs10886471 was performed using PCR-based methods. Logistic regression analysis revealed a modest but statistically significant association between the GRK5 A allele and favorable response to repaglinide (OR: 1.26; 95% CI: 1.01–1.57; p=0.048). Additionally, higher BMI and positive family history were linked to reduced therapeutic response. These findings suggest that GRK5 rs10886471 contributes to inter-individual variability in repaglinide efficacy, supporting the role of pharmacogenetic profiling in optimizing T2DM management. Incorporating both genetic and clinical factors may enhance individualized treatment strategies, minimize trial-and-error prescribing, and improve glycemic outcomes in diverse populations. While further multicenter studies with larger sample sizes are warranted to validate these results, this study provides important evidence for integrating GRK5 genotyping into personalized diabetes therapy.

Downloads

Download data is not yet available.

References

1. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., ... & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 21(17), 6275.

https://doi.org/10.3390/ijms21176275

2. Rachdaoui, N. (2020). Insulin: the friend and the foe in the development of type 2 diabetes mellitus. International journal of molecular sciences, 21(5), 1770.

https://doi.org/10.3390/ijms21051770

3. Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., ... & Xu, Q. (2023). Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology, 14, 1161521.

https://doi.org/10.3389/fendo.2023.1161521

4. Borse, S. P., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2021). Management of type 2 diabetes: current strategies, unfocussed aspects, challenges, and alternatives. Medical Principles and Practice, 30(2), 109-121.

https://doi.org/10.1159/000511002

5. Aslam, R., Suhail, S., Sajid, R., & bin Younis, B. (2022). Type 2 diabetes mellitus (T2DM) in Pakistan: prevalence, trends and management strategies. Annals of King Edward Medical University, 28(2), 247-254.

https://doi.org/10.21649/akemu.v28i2.5117

6. Siddiqui, I., Baig, M. M., & Khan, N. A. (2024). Environmental and Lifestyle Determinants of Type 2 Diabetes Mellitus.

https://doi.org/10.21203/rs.3.rs-4738489/v1

7. Noreen, Z., Loffredo, C. A., Bhatti, A., Simhadri, J. J., Nunlee-Bland, G., Nnanabu, T., ... & Ghosh, S. (2020). Transcriptional profiling and biological pathway (s) analysis of type 2 diabetes mellitus in a Pakistani population. International Journal of Environmental Research and Public Health, 17(16), 5866.

https://doi.org/10.3390/ijerph17165866

8. Malin, S. K., & Stewart, N. R. (2020). Metformin may contribute to inter-individual variability for glycemic responses to exercise. Frontiers in Endocrinology, 11, 519.

https://doi.org/10.3389/fendo.2020.00519

9. Anwardeen, N. R., Naja, K., & Elrayess, M. A. (2024). Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes. Frontiers in Pharmacology, 15, 1506767.

https://doi.org/10.3389/fphar.2024.1506767

10. El Desoky, E. S. (2022). Therapeutic dilemma in personalized medicine. Current Reviews in Clinical and Experimental Pharmacology Formerly Current Clinical Pharmacology, 17(2), 94-102.

https://doi.org/10.2174/1574884716666210525153454

11. Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Subramanian, T., Kurian, S. J., Miraj, S. S., ... & Munisamy, M. (2021). Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice. Pharmacogenomics and Personalized Medicine, 1441-1455.

https://doi.org/10.2147/pgpm.s329787

12. Engwa, G. A., Nweke, F. N., Karngong, G. N., Afiukwa, C. A., & Nwagu, K. E. (2020). Understanding the pathogenesis, therapeutic targets/drug action and pharmacogenetics of type 2 diabetes: is there a future for personalised medicine? Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 20(10), 1569-1589.

https://doi.org/10.2174/1871530320666200425202312

13. Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M., & Glotov, A. S. (2020). Pharmacogenetics of type 2 diabetes—progress and prospects. International Journal of Molecular Sciences, 21(18), 6842.

https://doi.org/10.3390/ijms21186842

14. Pei, X., Huang, D., & Li, Z. (2024). Genetic insights and emerging therapeutics in diabetic retinopathy: from molecular pathways to personalized medicine. Frontiers in Genetics, 15, 1416924.

https://doi.org/10.3389/fgene.2024.1416924

15. Hasanzad, M., Sarhangi, N., Hashemian, L., & Sarrami, B. (2022). Principles of pharmacogenomics and pharmacogenetics. In Precision medicine in clinical practice (pp. 13-32). Singapore: Springer Nature Singapore.

https://doi.org/10.1007/978-981-19-5082-7_2

16. Feingold, K. R. (2024). Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet].

17. Kupai, K., Várkonyi, T., Török, S., Gáti, V., Czimmerer, Z., Puskás, L. G., & Szebeni, G. J. (2022). Recent progress in the diagnosis and management of type 2 diabetes mellitus in the era of COVID-19 and single cell multi-omics technologies. Life, 12(8), 1205.

https://doi.org/10.3390/life12081205

18. Marzano, F., Rapacciuolo, A., Ferrara, N., Rengo, G., Koch, W. J., & Cannavo, A. (2021). Targeting GRK5 for treating chronic degenerative diseases. International Journal of Molecular Sciences, 22(4), 1920.

https://doi.org/10.3390/ijms22041920

19. Du, J., Wu, X., & Ni, L. (2024). The roles of G protein‐coupled receptor kinase 2 in renal diseases. Journal of Cellular and Molecular Medicine, 28(20), e70154.

https://doi.org/10.1111/jcmm.70154

20. Xu, M., Shao, Y., Lin, K., Liu, Y., Lin, Y., Lin, Y., ... & He, J. (2023). Genetic Arg-304-his substitution in GRK5 protects against sepsis progression by alleviating NF-κB-mediated inflammation. International Immunopharmacology, 115, 109629.

https://doi.org/10.1016/j.intimp.2022.109629

21. Wu, Y., Jensen, N., Rossner, M. J., & Wehr, M. C. (2024). Exploiting cell-based assays to accelerate drug development for G protein-coupled receptors. International Journal of Molecular Sciences, 25(10), 5474.

https://doi.org/10.3390/ijms25105474

22. Song, C., Ding, C., Yuan, F., Feng, G., Ma, Y., & Liu, A. (2020). Ten SNPs may affect type 2 diabetes risk in interaction with prenatal exposure to Chinese famine. Nutrients, 12(12), 3880.

https://doi.org/10.3390/nu12123880

23. Sasaki S, Nian C, Xu EE, Pasula DJ, Winata H, Grover S, Luciani DS, Lynn FC. Type 2 diabetes susceptibility gene GRK5 regulates physiological pancreatic β-cell proliferation via phosphorylation of HDAC5. iScience. 2023 Jul 10;26(8):107311. PMID: 37520700; PMCID: PMC10382860.

https://doi.org/10.1016/j.isci.2023.107311

24. Ijaz, K., Shah, H., Ali, S., Raziq, M., & Bahadar, H. (2024). Association of GRK5 variant rs10886471 with the therapeutic effect of repaglinide in patients of type 2 diabetes mellitus in Peshawar, Pakistan. Pakistan Journal of Pharmaceutical Sciences, 37.